Lenalidomide Zentiva

Lenalidomide, the active ingredient in Lenalidomide Zentiva, is an immunomodulatory drug (IMiD) presented as a tablet for oral use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in adult patients, and works by modulating immune response and inhibiting tumor cell proliferation.

GNH USA supplies Lenalidomide Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company ensures quality assurance, regulatory compliance and reliable logistics for global distribution.

Lenalidomide is used in hematologic malignancies that involve abnormal plasma or lymphoid cells. - Multiple Myeloma: reduces disease progression and improves survival in adult patients. - Myelodysplastic Syndromes with del(5q): corrects anemia and reduces transfusion dependence. - Mantle Cell Lymphoma: induces remission in relapsed or refractory disease.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may lead to dehydration. - Rash: skin redness or itching. - Neutropenia: reduced neutrophil count increasing infection risk.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Secondary primary malignancies: emergence of new cancers during therapy.

Before initiating lenalidomide therapy, several safety considerations should be reviewed. - Pregnancy risk: contraindicated in pregnancy (Category X); ensure effective contraception. - Thromboembolism: assess risk factors and consider prophylactic anticoagulation. - Hematologic monitoring: perform regular complete blood counts to detect cytopenias. - Renal impairment: adjust dosing and monitor renal function in patients with reduced clearance. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Lenalidomide interacts with several drugs that can alter its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce lenalidomide exposure (e.g., rifampin). - Anticoagulants (warfarin, DOACs): increase bleeding risk; close monitoring required.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., cyclosporine): may increase toxicity. - Live vaccines: reduced efficacy and risk of infection. - NSAIDs: may exacerbate renal toxicity. - Hormonal contraceptives: may be less effective; use additional non‑hormonal methods.